Global Rheumatoid Arthritis Market Report: 2016 Edition
Arthritis means inflammation in a joint. Inflammation is a normal immune response in a body. It happens when the body, no longer has the ability to turn off the inflammatory response and thereby start damaging the healthy tissues of the body. This inflammation causes redness, warmth, swelling, and pain within the joint. There are more than 100 different types of arthritis, with different causes and treatment methods. Major classification of arthritis includes degenerative arthritis, inflammation arthritis, infectious and metabolic arthritis.
Rheumatoid arthritis or RA is classified under inflammatory arthritis. It is a chronic autoimmune disease. About 1 out of every 5 people who suffer from rheumatoid arthritis get lumps on their skin called rheumatoid nodules. This disease occurs in 4 main stages and can be diagnosed with certain blood tests, medical history, and imaging tests. There is no cure for rheumatoid arthritis, but there are various treatments available that reduce the pain like drugs, physical exercise or surgery.
The rheumatoid arthritis market is expected to grow in the coming years with growing demand for better medical facilities and more effective drugs. The US rheumatoid arthritis market dominates the global market with larger number of rheumatoid arthritis patients. The key trends of the market include increasing competition from anti-IL6 drugs, rising FDA approvals to RA drugs, use of complementary and alternative medicines, and increasing share of biosimilars.
The key factors driving the growth of the RA market includes increasing women population, escalating global ageing population, rising health care expenditure, rising cigarette consumption, and increasing obese population. However, there are certain factors which hinder the growth of the rheumatoid arthritis market like high cost of treatment and high research and development cost.
The report offers an in-depth analysis of the “Global Rheumatoid Arthritis Market” segmented into global and regional market. Competition is concentrated in the hands of few major pharmaceutical companies. Major RA companies that have been covered in the report include AbbVie, JNJ, Amgen Inc. and Pfizer Inc.
Rheumatoid arthritis or RA is classified under inflammatory arthritis. It is a chronic autoimmune disease. About 1 out of every 5 people who suffer from rheumatoid arthritis get lumps on their skin called rheumatoid nodules. This disease occurs in 4 main stages and can be diagnosed with certain blood tests, medical history, and imaging tests. There is no cure for rheumatoid arthritis, but there are various treatments available that reduce the pain like drugs, physical exercise or surgery.
The rheumatoid arthritis market is expected to grow in the coming years with growing demand for better medical facilities and more effective drugs. The US rheumatoid arthritis market dominates the global market with larger number of rheumatoid arthritis patients. The key trends of the market include increasing competition from anti-IL6 drugs, rising FDA approvals to RA drugs, use of complementary and alternative medicines, and increasing share of biosimilars.
The key factors driving the growth of the RA market includes increasing women population, escalating global ageing population, rising health care expenditure, rising cigarette consumption, and increasing obese population. However, there are certain factors which hinder the growth of the rheumatoid arthritis market like high cost of treatment and high research and development cost.
The report offers an in-depth analysis of the “Global Rheumatoid Arthritis Market” segmented into global and regional market. Competition is concentrated in the hands of few major pharmaceutical companies. Major RA companies that have been covered in the report include AbbVie, JNJ, Amgen Inc. and Pfizer Inc.
1. MARKET OVERVIEW
1.1 Arthritis
1.2 Types of Arthritis
1.2 Rheumatoid Arthritis
1.3 Causes
1.4 Stage
1.5 Diagnosis
1.6 Treatment Options
2 GLOBAL MARKET
2.1 Global Rheumatoid Arthritis Market by Value
2.2 Global Rheumatoid Arthritis Market by Drug Class
2.3 Global Rheumatoid Market Share by Drug
2.4 Global Rheumatoid Arthritis Market Share by Biologics
3. THE U.S. MARKET
3.1 The US Rheumatoid Arthritis Market by Value
3.2 The US Rheumatoid Arthritis Patient Prevalence
3.3 The US Rheumatoid Arthritis Patient Penetration
3.4 The US Rheumatoid Arthritis Anti-TNF Population
3.5 The US Rheumatoid Arthritis Biologics Population
4. MARKET DYNAMICS
4.1 Key Trends
4.1.1 Increasing Competition from Anti-IL-6 Drugs
4.1.2 Rising FDA Approvals to Rheumatoid Arthritis Drugs
4.1.3 Auto-Injectors for Rheumatoid Arthritis
4.1.4 Use of Complementary and Alternative Medicines (CAMs)
4.1.5 Increasing Biosimilars for Rheumatoid Arthritis
4.2 Growth Drivers
4.2.1 Increasing Female Population Worldwide
4.2.2 Escalating Global Ageing Population
4.2.3 Rising Global Health Care Expenditure
4.2.4 Rising Cigarette Consumption
4.2.5 Increasing Obese Population
4.3 Challenges
4.3.1 High Cost of Treatment
4.3.3 High R&D Cost
5. COMPETITIVE LANDSCAPE
5.1 Global Market
5.1.1 Rheumatoid Arthritis Market Share by Company
5.1.2 Rheumatoid Arthritis Market Competition by Anti-TNF
5.1.3 Rheumatoid Arthritis Competition by Biologics
5.2 The US Market
5.2.1 Rheumatoid Arthritis Brand (Company) Share
6. COMPANY PROFILES
6.1 AbbVie
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Johnson & Johnson
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Amgen Inc.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Pfizer Inc.
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
1.1 Arthritis
1.2 Types of Arthritis
1.2 Rheumatoid Arthritis
1.3 Causes
1.4 Stage
1.5 Diagnosis
1.6 Treatment Options
2 GLOBAL MARKET
2.1 Global Rheumatoid Arthritis Market by Value
2.2 Global Rheumatoid Arthritis Market by Drug Class
2.3 Global Rheumatoid Market Share by Drug
2.4 Global Rheumatoid Arthritis Market Share by Biologics
3. THE U.S. MARKET
3.1 The US Rheumatoid Arthritis Market by Value
3.2 The US Rheumatoid Arthritis Patient Prevalence
3.3 The US Rheumatoid Arthritis Patient Penetration
3.4 The US Rheumatoid Arthritis Anti-TNF Population
3.5 The US Rheumatoid Arthritis Biologics Population
4. MARKET DYNAMICS
4.1 Key Trends
4.1.1 Increasing Competition from Anti-IL-6 Drugs
4.1.2 Rising FDA Approvals to Rheumatoid Arthritis Drugs
4.1.3 Auto-Injectors for Rheumatoid Arthritis
4.1.4 Use of Complementary and Alternative Medicines (CAMs)
4.1.5 Increasing Biosimilars for Rheumatoid Arthritis
4.2 Growth Drivers
4.2.1 Increasing Female Population Worldwide
4.2.2 Escalating Global Ageing Population
4.2.3 Rising Global Health Care Expenditure
4.2.4 Rising Cigarette Consumption
4.2.5 Increasing Obese Population
4.3 Challenges
4.3.1 High Cost of Treatment
4.3.3 High R&D Cost
5. COMPETITIVE LANDSCAPE
5.1 Global Market
5.1.1 Rheumatoid Arthritis Market Share by Company
5.1.2 Rheumatoid Arthritis Market Competition by Anti-TNF
5.1.3 Rheumatoid Arthritis Competition by Biologics
5.2 The US Market
5.2.1 Rheumatoid Arthritis Brand (Company) Share
6. COMPANY PROFILES
6.1 AbbVie
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Johnson & Johnson
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Amgen Inc.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Pfizer Inc.
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
LIST OF CHARTS
Types of Arthritis
Global Rheumatoid Arthritis Market by Value (2015-2020E)
Global Rheumatoid Arthritis Market by Drug Class (2015/2020E)
Global Rheumatoid Arthritis Market Share by Drug (2016E)
Global Rheumatoid Arthritis Market Share by Biologics (2015)
The US Rheumatoid Arthritis Market by Value (2015-2020E)
The US Rheumatoid Arthritis Patient Prevalence (2015-2020E)
The US Rheumatoid Arthritis Patient Penetration Rate (2015-2020E)
The US Rheumatoid Arthritis Anti-TNF Population (2015-2020E)
The US Rheumatoid Arthritis Biologics Population (2015-2020E)
Global Female Population (2010-2015)
Increasing Global Ageing Population of 60 Years or Older (2000-2030E)
Global Healthcare Expenditure (2009-2015E)
Increasing Cigarette Consumption (1910-2014)
Increasing Obese Population (2010-2015E)
Rheumatoid Arthritis Drug Prices (2013-2016E)
Rheumatoid Arthritis Market Share by Company (2015/2020E)
The US Rheumatoid Arthritis Brand (Company) Share (2016E)
Abbvie Revenue Share by Pharmaceutical Products (2015)
Abbvie Revenue Share by Region (2015)
Abbvie Revenue and Net Income (2012-2015)
Abbvie Research and Development Expenditure (2015)
Johnson & Johnson Revenue by Segment (2015)
Johnson & Johnson Revenue and Net Income (2012-2015)
Amgen Revenue Share by Products (2015)
Amgen Revenue and Net Income (2012-2015)
Pfizer Inc. Revenue by Segment (2015)
Pfizer Inc. Revenue and Net Income (2012-2015)
Types of Arthritis
Global Rheumatoid Arthritis Market by Value (2015-2020E)
Global Rheumatoid Arthritis Market by Drug Class (2015/2020E)
Global Rheumatoid Arthritis Market Share by Drug (2016E)
Global Rheumatoid Arthritis Market Share by Biologics (2015)
The US Rheumatoid Arthritis Market by Value (2015-2020E)
The US Rheumatoid Arthritis Patient Prevalence (2015-2020E)
The US Rheumatoid Arthritis Patient Penetration Rate (2015-2020E)
The US Rheumatoid Arthritis Anti-TNF Population (2015-2020E)
The US Rheumatoid Arthritis Biologics Population (2015-2020E)
Global Female Population (2010-2015)
Increasing Global Ageing Population of 60 Years or Older (2000-2030E)
Global Healthcare Expenditure (2009-2015E)
Increasing Cigarette Consumption (1910-2014)
Increasing Obese Population (2010-2015E)
Rheumatoid Arthritis Drug Prices (2013-2016E)
Rheumatoid Arthritis Market Share by Company (2015/2020E)
The US Rheumatoid Arthritis Brand (Company) Share (2016E)
Abbvie Revenue Share by Pharmaceutical Products (2015)
Abbvie Revenue Share by Region (2015)
Abbvie Revenue and Net Income (2012-2015)
Abbvie Research and Development Expenditure (2015)
Johnson & Johnson Revenue by Segment (2015)
Johnson & Johnson Revenue and Net Income (2012-2015)
Amgen Revenue Share by Products (2015)
Amgen Revenue and Net Income (2012-2015)
Pfizer Inc. Revenue by Segment (2015)
Pfizer Inc. Revenue and Net Income (2012-2015)
LIST OF TABLES
Development Progress of Anti-IL-6 Drugs for RA (2015)
Rheumatoid Arthritis Drug Approval and Developments (2015)
Use of Complementary and Alternative Medicines (2015)
Clinical Development of Biosimilars in Rheumatoid Arthritis (2015)
Global Rheumatoid Arthritis Competition by Biologics (2015)
New Products of Pfizer with FDA Approval (2015/2016)
New Innovative Product Portfolio of Johnson & Johnson (2015)
New Products of Pfizer with FDA Approval (2015/2016)
Development Progress of Anti-IL-6 Drugs for RA (2015)
Rheumatoid Arthritis Drug Approval and Developments (2015)
Use of Complementary and Alternative Medicines (2015)
Clinical Development of Biosimilars in Rheumatoid Arthritis (2015)
Global Rheumatoid Arthritis Competition by Biologics (2015)
New Products of Pfizer with FDA Approval (2015/2016)
New Innovative Product Portfolio of Johnson & Johnson (2015)
New Products of Pfizer with FDA Approval (2015/2016)
